SCHEMBL22323930

SCHEMBL22323930

COc1ccc(COc2nc(Cl)ncc2I)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APP P05067 8/20 0.50
CNR1 P21554 2/20 0.43
CNR2 P34972 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PIN1 Q13526 1/20 0.42
MAOB P27338 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
IDO1 P14902 1/20 0.40
AGXT P21549 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PDE2A O00408 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9987222 0.84 CNR1 (0.44) APPCNR1CNR2MEN1KMT2A
SCHEMBL31514820 0.83 CNR1 (0.43) APPCNR1CNR2MEN1KMT2A
SCHEMBL846643 0.83 POLB (0.47) APPCNR1CNR2PIN1MAOB
SCHEMBL3196355 0.83 CNR1 (0.43) APPCNR1CNR2MEN1KMT2A
SCHEMBL10201397 0.82 PIN1 (0.59) APPCNR1CNR2PIN1ALDH1A1
SCHEMBL9987333 0.82 MAOB (0.44) APPCNR1CNR2MEN1KMT2A
SCHEMBL9987933 0.82 PIN1 (0.44) APPCNR1CNR2PIN1MAOB
SCHEMBL20565236 0.80 AR (0.43) APPCNR1CNR2PIN1MAOB
SCHEMBL20564007 0.79 HTR6 (0.40) APPCNR1CNR2PIN1MAOB
SCHEMBL16685622 0.77 NPC1 (0.48) APPMEN1KMT2AMAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 APP 557/4885CNR1 4385/4885CNR2 4695/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 APP 1930/4885CNR1 1597/4885CNR2 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.